KRTAP13-3

Across TCGA pan-cancer cohorts, KRTAP13-3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRTAP13-3 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KRTAP13-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP13-3 expression acts as an unfavorable survival marker.

LUSC, LUAD, and SKCM are the cancer types where KRTAP13-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	30	view →
LUAD	DFS	Median	All	0.171	0.659	<.001	18	view →
SKCM	DFS	Median	III,IV	0.158	0.600	.010	10	view →
LIHC	DFS	Median	All	0.093	0.543	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KRTAP13-3–LUSC (OS)

Open the LUSC breakdown →